Original Source(s)
Related Content
FDA approves combo for ESR1-mutated breast cancer
In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.
September 21, 2026
-
2 min
FDA clears targeted cholangiocarcinoma therapy
In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.
September 24, 2026
-
2 min
Strengthen your PD-L1 expertise
The Precision Pathology Insights webinar series provides expert guidance and essential approaches to help enhance your confidence in Combined Positive Score (CPS) evaluation and strengthen your PD-L1 proficiency.
October 6, 2026
-
1 min
